Drug intelligence / Profile preview

NVA2301-10

Development stage: Preclinical
Lead developer: Novassay
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

NVA2301-10 is a preclinical-stage monoclonal antibody developed by Novassay that targets the α2δ-1 subunit of voltage-gated calcium channels. While α2δ-1 is traditionally recognized as the binding site for gabapentinoids used in neuropathic pain management, Novassay is exploring its therapeutic potential in oncology and neurodegeneration. The antibody is currently in lead optimization for the treatment of pancreatic cancer, leukemia, multiple myeloma, Alzheimer's disease, Parkinson's disease, and multiple sclerosis.

Targets

CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)

Beyond the preview

Go deeper on NVA2301-10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NVA2301-10.

Explore the full profile